依奇珠单抗阻断IL17A抑制临床银屑病中的MuvB信号传导
本研究对接受抗IL17A抗体依奇珠单抗(IXE)治疗的斑块状银屑病患者皮损进行纵向转录组分析,并与超过7亿数据点的已发表银屑病及信号节点扰动数据集比对。发现银屑病诱导基因和IXE抑制基因均富集MuvB复合体靶基因及G2/M细胞周期通路,IXE抑制的MuvB靶基因与疾病严重程度相关。在人角质形成细胞模型中,MuvB节点基因被IXE转录抑制,敲低MuvB节点可减少细胞增殖。
要点
- 银屑病皮损中MuvB复合体靶基因在疾病诱导基因和IXE抑制基因中均富集。
- IXE抑制的MuvB靶基因表达与银屑病疾病范围和严重程度强相关。
- 人角质形成细胞中IXE转录抑制MuvB节点基因,敲低MuvB节点减少细胞增殖。
核心结论
- 抑制MuvB信号传导是IXE治疗银屑病疗效的重要决定因素。
研究设计与样本
- 对参加抗IL17A抗体依奇珠单抗(IXE)临床试验的斑块状银屑病患者皮损生成纵向转录组图谱。
- 将数据集与来自已发表银屑病及信号节点扰动转录组和染色质免疫沉淀测序数据集的超过7亿数据点的 curated 矩阵进行计算机比对。
- 在人角质形成细胞增殖模型中进行验证。
主要发现
- 银屑病诱导基因集和IXE抑制基因集均富集MuvB复合体成员的转录靶标。
- 上述基因集同样富集参与细胞周期G2/M转换调控的通路。
- MuvB节点的转录靶标在IXE抑制基因中强烈富集,且这些基因表达水平与银屑病疾病范围和严重程度强相关。
- 在人角质形成细胞增殖模型中,编码MuvB节点的基因被IXE转录抑制,敲低MuvB节点减少细胞增殖。
- 支持本研究的表达和调控网络已作为免费可访问的云端假设生成平台提供。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Unbiased informatics approaches have the potential to generate insights into uncharacterized signaling pathways in human disease. In this study, we generated longitudinal transcriptomic profiles of plaque psoriasis lesions from patients enrolled in a clinical trial of the anti-IL17A antibody ixekizumab (IXE). This dataset was then computed against a curated matrix of over 700 million data points derived from published psoriasis and signaling node perturbation transcriptomic and chromatin immunoprecipitation-sequencing datasets. We observed substantive enrichment within both psoriasis-induced and IXE-repressed gene sets of transcriptional targets of members of the MuvB complex, a master regulator of the mitotic cell cycle. These gene sets were similarly enriched for pathways involved in the regulation of the G2/M transition of the cell cycle. Moreover, transcriptional targets for MuvB nodes were strongly enriched within IXE-repressed genes whose expression levels correlated strongly with the extent and severity of the psoriatic disease. In models of human keratinocyte proliferation, genes encoding MuvB nodes were transcriptionally repressed by IXE, and depletion of MuvB nodes reduced cell proliferation. Finally, we made the expression and regulatory networks that supported this study available as a freely accessible, cloud-based hypothesis generation platform. Our study positions inhibition of MuvB signaling as an important determinant of the therapeutic impact of IXE in psoriasis.
引用
- Ochsner SA, Pedroza M, Pillich RT, et al. IL17A Blockade with Ixekizumab Suppresses MuvB Signaling in Clinical Psoriasis. J Invest Dermatol. 2023. PMID: 36967086. doi:10.1016/j.jid.2023.03.1658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。